Tenax Therapeutics Inc expected to post a loss of 24 cents a share - Earnings Preview

Tenax Therapeutics

08/08/2025 22:42

Tenax Therapeutics Inc TENX.OQ TENX.O is expected to  show no change in quarterly revenue when it reports  results on August 11 (estimated) for the period ending June 30 2025

​LSEG's mean analyst estimate for Tenax Therapeutics Inc is for a loss of 24 cents per share.

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Tenax Therapeutics Inc is $16.00, about 62.6% above its last closing price of $5.98

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-0.19
-0.19
-0.28
Missed
-44.8
Dec. 31 2025
-0.15
-0.42
-0.18
Beat
57.4
Sep. 30 2024
-1.40
-1.39
-0.19
Beat
86.3​
Jun. 30 2024
-1.99
-1.98
-1.83
Beat
7.8
​​Mar. 31 2024
-2.48
-2.40
-3.12
Missed
-30
Dec. 31 2023
-8.11
-8.14
-12.98
Missed
-59.4​
Sep. 30 2023
-4.80
-7.20
-6.40
Beat
11.1
Jun. 30 2023
-7.90
-8.00
-4.00
Beat
50

This summary was machine generated August 8 at 21:42 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)